Boston, MA -- (ReleaseWire) -- 04/17/2014 -- The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
View Full Report Details and Table of Contents
This report contains over 2,000 links to online copies of actual clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner clinical stage compounds/products.
Chapter 3 provides an overview of clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in clinical stage deals.
Chapter 5 provides a review of clinical stage deal making since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 6 provides a detailed analysis of clinical stage payment terms including average headline, upfront, milestone and royalty rates for phase I, phase II and phase III deals.
Chapter 7 provides a review of the leading clinical stage deal by headline value.
Companies Mentioned in this Report: Abbott, Actavis, Allergan, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Endo, Forest, Fresenius, Galderma, Gilead Sciences, GlaxoSmithKline, Grifols, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Lundbeck, Menarini, Merck & Co, Merck KGaA, Mitsubishi Tanabe, Mylan, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue, Ranbaxy, Roche, Sanofi, Servier, Shionogi, Shire, Stada, Takeda, Teva, UCB view, Valeant, Warner Chilcott
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Discovery Stage Partnering Terms and Agreements
- Infectious Vaccines Partnering Terms and Agreements
- Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Bioinformatics Partnering Terms and Agreements
- Antibody Partnering Terms and Agreements
- Antibiotics Partnering Terms and Agreements
- Cancer Monoclonal Antibody Partnering Terms and Agreements
- Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
- Vaccine Partnering Terms and Agreements